Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.4K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.4K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

1.2K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.2K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.0K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.0K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

1.3K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.3K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

664
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
664
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

1.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical usefulness of anti-α3Gal immunoglobulin E assays for cetuximab-mediated anaphylaxis in head and neck cancer.

Immuno-oncology technology·2025
Same author

Evaluation of efficacy and safety of rituximab in combination with mycophenolate mofetil in patients with nonspecific interstitial pneumonia non-responding to a first-line immunosuppressive treatment (EVER-ILD): A double-blind placebo-controlled randomized trial.

Respiratory medicine and research·2020
Same author

Association between difference in blood pressure reduction and risk of cardiovascular events in a type 2 diabetes population: A meta-regression analysis.

Diabetes & metabolism·2019
Same author

A systematic review of the learning curve in robotic surgery: range and heterogeneity.

Surgical endoscopy·2018
Same author

The CRAC cohort model: A computerized low cost registry of interventional cardiology with daily update and long-term follow-up.

Revue d'epidemiologie et de sante publique·2018
Same author

[Drugs news].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2017
Same journal

[Abdominal pain, fever and arthralgia in a 49-year-old woman].

La Revue de medecine interne·2026
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

[Diagnostic evaluation for suspected polycythemia].

La Revue de medecine interne·2026
Same journal

Heart involvements in systemic sclerosis beyond pulmonary hypertension: From conduction, rhythm and function defects to coronary artery disease.

La Revue de medecine interne·2026
Same journal

[Acute intermittent porphyria: When diagnostic errance jeopardizes patient health].

La Revue de medecine interne·2026
Same journal

Autosomal dominant polycystic kidney disease: Current perspectives in 2026.

La Revue de medecine interne·2026
See all related articles

Related Experiment Video

Updated: Dec 18, 2025

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
09:17

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

Published on: August 9, 2022

2.4K

[Update on beta blockers in 2020].

T Bejan-Angoulvant1, D Angoulvant2

  • 1Service de Pharmacologie Médicale, CHRU et Université de Tours. Hôpital Bretonneau, 2 boulevard Tonnellé - 37044 Tours cedex 9, France.

La Revue De Medecine Interne
|June 14, 2020
PubMed
Summary
This summary is machine-generated.

Beta-blockers (BB) are vital for cardiovascular diseases like heart failure and angina, despite not being first-line for hypertension. Research explores their potential use in COPD and cancer.

Keywords:
Adverse eventsBeta-blockersBêtabloquantsDrug repositioningEffets indésirablesIndicationsPharmacologiePharmacologyRepositionnement thérapeutique

More Related Videos

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

3.6K
Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

1.9K

Related Experiment Videos

Last Updated: Dec 18, 2025

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
09:17

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

Published on: August 9, 2022

2.4K
Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

3.6K
Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

1.9K

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Oncology

Background:

  • Beta-blockers (BB) are a diverse group of drugs that block beta-adrenergic receptors.
  • Their efficacy varies based on effects on adrenergic signaling.
  • While not first-line for hypertension, they are crucial for managing cardiovascular conditions.

Purpose of the Study:

  • To review the fundamental pharmacology of beta-blockers.
  • To detail established indications for beta-blocker use.
  • To explore emerging therapeutic applications of beta-blockers.

Main Methods:

  • This is a narrative review.
  • It synthesizes existing pharmacological knowledge on beta-blockers.
  • It discusses current and potential clinical applications.

Main Results:

  • Beta-blockers remain essential for stable angina, heart failure, arrhythmia, and aortic diseases.
  • Established non-cardiovascular uses include migraine, hepatic cirrhosis, glaucoma, infantile hemangioma, and hyperthyroidism.
  • Emerging research investigates therapeutic repurposing in COPD and cancer.

Conclusions:

  • Beta-blockers possess a broad spectrum of applications beyond their initial cardiovascular focus.
  • Understanding their pharmacology is key for effective clinical use.
  • Ongoing research may expand the therapeutic landscape for beta-blockers, including in oncology and respiratory diseases.